ClinicalTrials.gg
RecruitingNCT05630794Updated Oct 15, 2026

Testing for Safety and Colorectal Cancer Preventive Effects of ONC201

A Phase 1 interventional study of Biopsy Procedure and Biospecimen Collection in Colorectal Adenomatous Polyp, Colorectal Carcinoma and Familial Adenomatous Polyposis, sponsored by National Cancer Institute (NCI). Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Primary conditionAdenomatous Polyposis ColiRegistry: Colorectal NeoplasmsReclassifiedWhy we changed it
Registry
Colorectal Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Adenomatous Polyposis Coli
Why
  1. The study's listed conditions name Adenomatous Polyposis Coli, a narrower term within Colorectal Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Cancer Institute (NCI) · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 7, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Adenomatous Polyposis Coli with a site in United States — 12 open to participants now, 12 under way, 1 of them phase 3. Adenomatous Polyposis Coli · United States.

Planned enrollment
16th of 27
36 · median 42
Started
2025
with 1 other
Phase 1
6 of 39
1 open now
Primary completion
2028-07
later than 7 of 11 live
Registered
32nd of 39
by date
Lead sponsor
8 of 39
National Cancer Institute (NCI)

Among the 39 studies in Adenomatous Polyposis Coli with a site in United States, this one is the 16th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 1, reaches primary completion later than 7 of the 11 other live ones, and was the 32nd registered.

Adenomatous Polyposis Coli

92 studies on the registry are indexed under Adenomatous Polyposis Coli; 28 are open to participants now.

Browse Adenomatous Polyposis Coli studies →

Open to participants now

12 of the 39 studies in Adenomatous Polyposis Coli with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Adenomatous Polyposis Coli studies recruiting now, 15 (75%) set no upper age limit and 2 (10%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Adenomatous Polyposis Coli with a site in United States, or all of them as a file.
02

Study summary

The purpose of this phase I trial is to test the safety and cancer preventive effects of different doses of ONC201 in people with familial adenomatous polyposis (FAP) or a history of multiple polyps. People with familial adenomatous polyposis (FAP) or a history of multiple polyps are at higher than average risk of developing colorectal cancer. ONC201, now known as dordaviprone, is a drug that may stop cancer cells from growing. This drug has been shown in previous studies to cause cancer cell death but not harm normal cells. If successful, this study may help us develop a new option for colorectal cancer prevention.

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate the safety and toxicity of dordaviprone (ONC201) for the indication of cancer prevention in a healthy population of individuals who are at high risk (FAP and/or history of multiple adenomas [excluding hereditary nonpolyposis colorectal cancer (HNPCC)]) for recurrent colorectal adenomas.

SECONDARY OBJECTIVES:

I. To determine the dose(s) of ONC201 that yield(s) a statistically significant increase in human adenoma tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression.

II. To determine the dose(s) of ONC201 that yield(s) a statistically significant increase in normal human mucosa TRAIL expression.

EXPLORATORY OBJECTIVES:

I. To evaluate the impact of ONC201 on:

Ia. Cytokine/immune response profiles (with attention to interleukin [IL]-10, IL-17A, tumor necrosis factor [TNF]-alpha, IL-6, granzyme A, and perforin) in sera, normal colonic mucosa, and adenomas; Ib. Serum TRAIL concentration; Ic. Serum prolactin concentration; Id. Proliferation markers (Ki67), cell death markers (BCL2, Caspase 3), stemness markers (LGR5, CD44, CD133, ALDH), and natural killer (NK) cell infiltration in adenomas and in normal colonic mucosa; Ie. To evaluate for associations between observed toxicity and TRAIL expression; If. To establish organoids ex vivo and compare adenoma-derived organoid take rates between samples obtained prior to and following treatment.

OUTLINE: This is a dose-escalation study.

Patients receive ONC201 orally (PO) once weekly (QW) or once every 3 weeks (Q3W) for 13 weeks. Patients also undergo collection of blood, tissue biopsy, and sigmoidoscopy/colonoscopy throughout the study. Additionally, patients undergo colonoscopy or lower endoscopic evaluation during screening.

After completion of study treatment, patients are followed up at 21-35 days.

03

Conditions studied

  • Colorectal Adenomatous Polyp
  • Colorectal Carcinoma
  • Familial Adenomatous Polyposis
  • Multiple Adenomatous Polyps

Browse trials for

04

In context

Adenomatous Polyposis Coli Reclassified

92 studies on the registry are indexed under Adenomatous Polyposis Coli; 28 are open to participants now.

This study's planned enrollment of 36 is close to the median of 40 across 61 interventional studies indexed under Adenomatous Polyposis Coli.

Browse Adenomatous Polyposis Coli studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 336 are open to participants now.

Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.

Compared within Adenomatous Polyposis Coli, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Colorectal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Oct 7, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be identified as high risk for recurrent colorectal adenomas, as defined by:

    • A diagnosis of FAP AND/OR
    • Findings of either > 5 small (less than 1 cm) adenomas OR >= 3 with at least one >= 10 mm on most recent colonoscopy performed in the past 5 years
  • Be >= 18 years of age on day of signing
  • Have an (ECOG) performance status =\< 1 ( >= 70%)
  • Leukocytes >= 3,000/microliter
  • >= 1,000/microliter
  • >= 100,000/microliter
  • Total within normal institutional limits
  • (AST) (serum (glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase ([SGPT]) =\< 1.5 x institutional
  • Creatinine =\< 1.5 x institutional upper limit of normal
  • Participant is due to undergo a standard of care lower gastrointestinal (GI) colonoscopy (in participants who have undergone prior colectomy and for whom colonoscopy is not feasible, an appropriate standard-of-care lower endoscopic evaluation may be substituted for the baseline colonoscopy at the site investigator's discretion) for detection and removal of colorectal polyps. On this colonoscopy, participant is required to have:

    • Two (2) adenomatous polyps of at least five (5) mm in size
    • At least one (1) polyp within reach of a flexible sigmoidoscope (which will be retained in the colon or rectum and marked)
    • In addition to polypectomy, six (6) of normal colonic mucosa >= 1 cm from a collected polyp will also be collected
  • Willing to undergo a second, research intent endoscopic procedure (either sigmoidoscopy or colonoscopy), approximately 12 weeks after initiating ONC201 treatment
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
  • of at least 5-years
  • ONC201 is an imipridone agent with the potential for teratogenic or abortifacient effects. For this reason and because imipridones potential teratogenic effects are unknown, men and women of must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for four weeks after study treatment is completed. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should STOP the study medication and inform her study physician immediately
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion criteria

Exclusion Criteria:

  • Prior history of hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome
  • Participants may not be currently receiving any other agents or have received any investigational agents within the past four weeks
  • Prior history of invasive colorectal cancer
  • Prior invasive active neoplasm that is progressing or requires active treatment within 3 years from registration. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. Participants with a history of prior invasive neoplasm diagnosed and treated greater than 3 years form registration may be considered with consultation of the primary investigator
  • Prior history of exposure to cytotoxic chemotherapy or ONC201
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant and women who are nursing are excluded from this study because ONC201 is an imipridone agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with ONC201, breastfeeding should be discontinued if the mother is treated with ONC201
  • Concomitant use of strong/moderate /5 inducers/inhibitors. These agents must be discontinued at least 72-hours prior to beginning ONC201
  • Any of the following cardiac criteria:

    • Prolongation of (QTc) interval (QTc interval > 480 milliseconds, preferably using Frederica's QT correction formula), confirmed on (ECG) tracings performed during screening
    • A history of Torsades de pointes, heart failure, or family history of prolonged QT Syndrome
  • Concomitant use of drugs that are known to prolong QT and have a known risk of torsade de pointes (TdP) unless they are willing to stop these medications and possibly change to an alternative non-excluded medication to treat the same condition at least 72 hours prior to beginning ONC201
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

06

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Prevention (ONC201, biopsy, sigmoidoscopy, colonoscopy)

    Patients receive ONC201 PO QW or Q3W for 13 weeks. Patients also undergo collection of blood, tissue biopsy, and sigmoidoscopy/colonoscopy throughout the study. Additionally, patients undergo colonoscopy or lower endoscopic evaluation during screening.

    Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Colonoscopy · Drug: Dordaviprone Hydrochloride · Procedure: Endoscopic Procedure · Other: Questionnaire Administration · Procedure: Sigmoidoscopy

Interventions

  • ProcedureBiopsy Procedure

    Undergo biopsy

    Also known as: Biopsy, BIOPSY_TYPE, Bx

  • ProcedureBiospecimen Collection

    Undergo collection of blood

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureColonoscopy

    Undergo colonoscopy

  • Given PO

    Also known as: Modeyso

  • ProcedureEndoscopic Procedure

    Undergo lower endoscopic evaluation

    Also known as: Endoscopic Examination, Endoscopy, ES

  • OtherQuestionnaire Administration

    Ancillary studies

  • ProcedureSigmoidoscopy

    Undergo sigmoidoscopy

    Also known as: Proctosigmoidoscopy

07

What researchers measure

Primary outcomes

  1. Proportion of participants with unacceptable toxicity

    Will be assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: Up to 35 days post last dose of ONC201

Secondary outcomes

  1. Mean change in human adenoma tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression in polyps induced by ONC201

    The TRAIL expression in polyps obtained during pre-treatment colonoscopy and again during sigmoidoscopy after 12 weeks of treatment will be measured. The mean difference in this change is compared between time points by means of a paired t-test. For skewed outcomes, the nonparametric Wilcoxon signed-rank test will be employed.

    Time frame: Baseline up to week 13 end of treatment

  2. Mean change in normal human mucosa TRAIL expression induced by ONC201

    The TRAIL expression in polyps obtained during pre-treatment colonoscopy and again during sigmoidoscopy after 12 weeks of treatment will be measured. The mean difference in this change is compared between time points by means of a paired t-test. For skewed outcomes, the nonparametric Wilcoxon signed-rank test will be employed.

    Time frame: Baseline up to week 13 end of treatment

Other outcomes

  1. Changes in mean cytokine/immune response levels (with attention to IL-10, IL-17A, TNFalpha, IL-6, granzyme A, and perforin) in sera, normal colonic mucosa, and adenomas between pre-, on-, and post-ONC201 treatment samples

    The mean difference in this change is compared between time points by means of a paired t-test. For skewed outcomes, the nonparametric Wilcoxon signed-rank test will be employed.

    Time frame: Baseline up to week 13 end of treatment

  2. Changes in mean serum TRAIL concentrations in pre-, on-, and post-treatment samples obtained from participants treated with escalating doses of ONC201

    The mean difference in this change is compared between time points by means of a paired t-test. For skewed outcomes, the nonparametric Wilcoxon signed-rank test will be employed.

    Time frame: Baseline up to week 13 end of treatment

  3. Changes in mean serum prolactin concentrations in pre-, on-, and post-treatment samples obtained from participants treated with escalating doses of ONC201

    The mean difference in this change is compared between time points by means of a paired t-test. For skewed outcomes, the nonparametric Wilcoxon signed-rank test will be employed.

    Time frame: Baseline up to week 13 end of treatment

  4. Changes in Ki67, BCL2, Caspase 3, LGR5, CD44, CD133, and ALDH staining and NK cell infiltration in adenomas and in normal colonic mucosa obtained from participants prior to and following treatment with escalating doses of ONC201

    The mean difference in this change is compared between time points by means of a paired t-test. For skewed outcomes, the nonparametric Wilcoxon signed-rank test will be employed.

    Time frame: Baseline up to week 13 end of treatment

  5. Mean change in TRAIL expression between those who experience adverse events versus those who do not

    Will be compared qualitatively.

    Time frame: Baseline up to week 13 end of treatment

  6. Adenoma-derived organoid take rates between samples obtained prior to and following treatment

    The mean difference in this change is compared between time points by means of a paired t-test. For skewed outcomes, the nonparametric Wilcoxon signed-rank test will be employed.

    Time frame: Baseline up to week 13 end of treatment

08

Study locations

3 of 5 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2025 (actual). Primary completion is estimated for Jul 2028, 32 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion May 2027 → Jul 2028 and completion Mar 2028 → May 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2022
First posted
Nov 30, 2022
StartActual
Oct 6, 2025
Primary completionEst.
Jul 1, 2028was May 2027
CompletionEst.
May 1, 2029was Mar 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 1, 2027→Jul 1, 2028
Oct 7, 2026
Study completion
Mar 1, 2028→May 1, 2029
Oct 7, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedParticipant is due to undergo a standard of care lower gastrointestinal (GI) colonoscopy (in participants who have undergone prior colectomy and for whom colonoscopy is not feasible, an appropriate standard-of-care lower endoscopic evaluation may be substituted for the baseline colonoscopy at the site investigator's discretion) for detection and removal of colorectal polyps. On this colonoscopy, participant is required to have:
Oct 7, 2026
Interventions
Added Procedure: Endoscopic Procedure
Oct 7, 2026
Show all 2 updates
  1. Oct 15, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 7, 2026
    Primary completion May 1, 2027→Jul 1, 2028
    Study completion Mar 1, 2028→May 1, 2029
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedParticipant is due to undergo a standard of care lower gastrointestinal (GI) colonoscopy (in participants who have undergone prior colectomy and for whom colonoscopy is not feasible, an appropriate standard-of-care lower endoscopic evaluation may be substituted for the baseline colonoscopy at the site investigator's discretion) for detection and removal of colorectal polyps. On this colonoscopy, participant is required to have:
    Interventions Added Procedure: Endoscopic Procedure
    + 3 other changes: registry dates, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05630794
Responsible party
Sponsor
First posted
Nov 30, 2022
Start date
Oct 6, 2025
Primary completion
Jul 1, 2028 (estimated)
Completion
May 1, 2029 (estimated)
Last update
Oct 15, 2026

Study contacts

Alexander G Raufi, MD
principal investigator · Brown University Health/ Rhode Island Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dordaviprone

Start the discussion